As of 1 January 2021, you may no longer be able to export branded medicines that have been placed on the UK market to countries in the European Economic Area (EEA).
Hoarding or exporting a medicine on the list is considered a breach of regulation 43(2) of the Human Medicines Regulations 2012 and a contravention of the wholesale dealer licence, and may lead to regulatory action by the Medicines and Healthcare products Regulatory Agency (MHRA), which could include immediate suspension of the wholesale dealer licence.
Published 3 October 2019 Last updated 14 November 2024 +show all updates
Updated to remove the following products: amiodarone (solution for injection), azithromycin, aztreonam (powder for solution for injection vials), bumetanide (tablets), bupivacaine + fentanyl (312.5mg/250ml (0.125%) + 500mg/250ml, 625mg/500ml (0.125%) + 1mg/500ml, solution for infusion), carbamazepine (100mg/5ml, oral suspension), dexamethasone, heparin, levomepromazine, linezolid, midazolam, oxycodone, paracetamol, permethrin (5%, cream), prochlorperazine, quetiapine, salbutamol (nebuliser liquid unit dose vials), sodium dihydrogen phosphate anhydrous (effervescent tablet), vinblastine (10mg/10ml, solution for injection vials).
Updated to add: Folinic acid (strength: 10mg/1ml, pharmaceutical form: solution for injection or infusion vials).
Updated to add the following product to the list: Peginterferon alfa-2a (strength: all, pharmaceutical form: solution for injection pre-filled syringes).
Added to the list: Quetiapine (strength: all, pharmaceutical form: all); Disopyramide (strength: all, pharmaceutical form: all); and Potassium Chloride (strength: all, pharmaceutical form: oral solution).
Updated to add the following products to the list: Pancreatin, Clarithromycin, Erythromycin, Azithromycin and Co-trimoxazole (all strengths and all pharmaceutical forms), and Carbamazepine (100mg/5ml, oral suspension).
Added to the list: Vinblastine (strength: 10mg/10ml, pharmaceutical form: solution for injection vials) and Aztreonam (strength: all, pharmaceutical form: powder for solution for injection vials).
Added to the list: Vitamin B substances with ascorbic acid.
Added the following product to the list: Salbutamol (strength: all, pharmaceutical form: nebuliser liquid unit dose vials).
Added the following products to the list: Iodixanol (strength: all, pharmaceutical form: solution for injection); Iohexol (strength: all, pharmaceutical form: solution for injection); Nadolol (strength: 80mg, pharmaceutical form: tablets); potassium chloride/potassium bicarbonate (strength: all, pharmaceutical form: effervescent tablet); sodium dihydrogen phosphate anhydrous (strength: all, pharmaceutical form: effervescent tablet).
Added the following product to the list: Olanzapine embonate: all strengths; powder and solvent for suspension for injection.
The following products have been added to the list of medicines: Hyoscine hydrobromide (strength: 1.5mg, pharmaceutical form: patches); Bumetanide (strength: all, pharmaceutical form: tablets); Methylphenidate hydrochloride (strength: all, pharmaceutical form: all); Atomoxetine (strength: all, pharmaceutical form: all); Lisdexamfetamine mesylate (strength: all, pharmaceutical form: all); Dexamfetamine sulfate (strength: all, pharmaceutical form: all); and Guanfacine (strength: all, pharmaceutical form: all).
The following products have been added: Ketamine; Bupivacaine + Fentanyl; Levobupivacaine; Human corticotrophin releasing hormone (hCRH) (Unlicenced). The following products have been removed: Ceftazidime; Cefuroxime; Co-trimoxazole; Cyclizine; Esomeprazole; Fentanyl; Hepatitis B vaccine; Hyoscine butylbromide; Influenza vaccine; In
